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INTRODUCTION
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Catheter placement. TIVAP implantation was performed as described previously (9) . Briefly, surgical 123 placement of TIVAP in anesthetized rats was carried out as follows: the port was implanted at the 124 dorsal midline toward the lower end of the thoracic vertebrae by creating a subcutaneous pocket. The 125 catheter was tunneled subcutaneously into the ventral side in the clavicle region, inserted into the 126 jugular vein by a micro-incision and progressively inserted into the superior vena cava up to the right 127 atrium. Patency of TIVAP was maintained by flushing 1X sterile PBS followed by heparin lock (500 128 IU/mL) every day. Prior to inoculation of clinical strains, all rats were checked for the absence of 129 infection by plating 100 µL blood, as well as monitoring for the absence of any luminescence signals. 
139
Immune suppression and infection in catheterized rats. The immune system of the rats was 140 suppressed using cyclophosphamide (Sigma Aldrich cat# C0768-5G). The optimized dose and 141 regimen of cyclophosphamide delivery, determined by estimating total blood leukocyte count using the 142 animal blood cell counter Vet ABC (SCIL, Germany), was used as described previously (9) 
165
The efficacy of gentamicin (5 mg/mL), EDTA (30 mg/mL), ethanol (70%) and gentamicin-EDTA (5 166 mg/mL-30 mg/mL) lock therapy was evaluated. All lock solutions were prepared in sterile distilled 
183
Gentamicin-EDTA efficacy against S. aureus in vivo catheter-associated biofilms.
184
To evaluate the in vivo efficacy of tetrasodium EDTA as a potential adjuvant in ALT, we tested 185 different gentamicin-based lock solutions against bioluminescent methicillin-susceptible S. aureus 186 (MSSA) biofilms growing in TIVAP implanted in rats (n=5 rats for each treatment). In addition to 187 solutions containing gentamicin alone, EDTA alone or combined gentamicin-EDTA, we evaluated 70% 188 ethanol, which was shown to be an effective antibacterial lock agent both in vitro and in vivo (11, 23).
189
We first used ALT instillations renewed every 24 h for 5 days in conjunction with systemic vancomycin 
201
While our results demonstrated the in vivo efficacy of a 5-day regimen of gentamicin-EDTA ALT 202 treatment against MSSA biofilms, we also sought to determine whether gentamicin-EDTA ALT would 203 reduce the length and frequency of ALT treatment. For this, we applied a single instillation of 204 gentamicin-EDTA lock solution in conjunction with systemic vancomycin injections on 3-day-old in vivo 205 MSSA biofilm (1-day regimen). After 1 day, we already observed an absence of luminescence and a 206 ∼4.2-log reduction in bacterial CFU/mL compared to rats with PBS ALT (day 1 in Figure 2A , 2C and 207 2E). Moreover, analysis of TIVAP 7 days after single gentamicin-EDTA ALT left to dwell for 7 days 208 (day 8) showed complete removal of bacteria from the catheters (day 8 in Figure 2A , 2C, 2D, and 209 Figure 2E ). Although a decrease in bioluminescence was observed, rats with PBS ALT displayed a 2-210 log-increase in bacterial colonization ( Figure 2B and 2E ). Indeed, bioluminescence will not detect 211 bacteria that are viable but are either dormant or growing anaerobically in TIVAP (9). Furthermore, the 9 absence of bacteria in gentamicin-EDTA-treated TIVAP was confirmed by scanning electron 213 microscopy. While TIVAP extracted from rats treated with either gentamicin or EDTA alone showed 214 the presence of biofilms with a dense bacterial population ( Figure 2F -G), TIVAP from rats treated with 215 gentamicin-EDTA ALT displayed only a meshwork of host-derived fibrin-like material and the absence 216 of bacteria ( Figure 2H ).
217
These results demonstrated that use of a single instillation of gentamicin-EDTA antibiotic lock solution 218 successfully eradicated catheter-associated biofilms formed in vivo by MSSA.
220
One-shot gentamicin-EDTA ALT is effective in immunosuppressed animals.
221
Immunosuppressed patients are highly susceptible to bloodstream infections associated with central 
237
In addition to MSSA infections, staphylococci-associated biofilm infections may also be due to 238 methicillin-resistant (MRSA) strains, while S. epidermidis is the most commonly reported bacterium in 239 catheter-related infections (9, 24, 30) . To test the efficacy of a single instillation of gentamicin-EDTA 240 against S. epidermidis and MRSA, we used two clinical bioluminescent strains of S. epidermidis 241 (Xen43) and MRSA (Xen31). These two strains are poorly luminescent in vivo and therefore did not 10 enable us to non-invasively monitor biofilm colonization in implanted TIVAP; however, both of them led 243 to formation of in vivo biofilm (Figure 4 and (9)). Although a single instillation of gentamicin-EDTA (1-244 day ALT regimen) eradicated S. epidermidis biofilm, ∼3-log CFU/mL bacteria could still be recovered 245 from TIVAP-associated MRSA biofilms (number of animals, n=3) ( Figure 4) . However, using a 5-day
246
ALT regimen, we demonstrated that in vivo TIVAP-associated MRSA biofilms could be successfully 247 eradicated with gentamicin-EDTA ALT, compared with gentamicin-treated biofilms where ∼6.2-log 248 CFU/mL bacteria were recovered (number of animals, n= 3) ( Figure 4 ).
250
The gentamicin-EDTA lock solution is efficient against Gram-negative bacteria. 
271
In the case of intermittently used devices, ALT is a widely used strategy recommended for prevention 272 or cure of intraluminal catheter-associated biofilms (30, 40 278 therefore enhance the antimicrobial effect of antibiotics (3, 6, 35, 53) .
279
In the present study, using our previously optimized rat model with an implanted TIVAP, we evaluated 280 the in vivo efficacy of the anticoagulant chelator tetrasodium EDTA, in combination with gentamicin, as 281 a potential curative antibiotic lock solution (9). For initial evaluation of EDTA as an adjuvant to the 282 gentamicin lock solution as compared to gentamicin alone, EDTA alone or ethanol, we chose S.
283
aureus catheter colonization, for which catheter removal is mandatory (16, 19) . We showed that the 284 gentamicin-EDTA combination was the most effective lock solution compared to gentamicin alone,
285
EDTA alone or ethanol (70%). Since, we previously demonstrated the risk of systemic infection when
286
ALT was used alone, we always used systemic antibiotics alongside (9). We chose systemic 287 vancomycin, even in case of methicillin-susceptible Staphylococcus spp. in order to compare the 288 effect of ALT between these different strains without having a bias related to various systemic 289 treatments. We also wanted to reproduce the first 24 or 48 hours of treatment during which antibiotic 290 susceptibility pattern is not determined and clinicians have to deal with a Gram-positive healthcare-291 associated bloodstream infection.
292
Ethanol alone or in combination is reported to be effective against in vitro biofilms as well as 293 decreasing CRBSI and the need for catheter replacement in clinical trials (21, 23, 32 
301
Recurrence of biofilm-associated infections due to the presence of highly antibiotic tolerant bacteria 302 within biofilms is one of the major challenges for catheter management in the clinical setting (12, 25, 
310
term catheter, improving patient outcome. We showed that a single instillation of gentamicin-EDTA
311
ALT, left to dwell for 7 days, effectively eradicated biofilms formed by MSSA and S. epidermidis, thus 312 probably reducing the possibility of recurrence. It is noteworthy that the MRSA strain used in this study 313 is gentamicin-resistant, like 3% of MSSA and 11% of MRSA in hospital-acquired S. aureus infections 314 in Texas (22). Nevertheless, use of a 5-day ALT regimen led to total eradication of in vivo TIVAP-315 associated MRSA biofilms, suggesting that the gentamicin-EDTA lock solution could still be used in 316 this setting. As EDTA was earlier shown to disrupt biofilm through metal chelation, we speculate that 317 the bacteria released would be more susceptible to the direct antibacterial effect of EDTA (see Table   318 1) (34). Besides, free-swimming bacteria may have been killed by gentamicin that still could have 319 some efficacy at such a high concentration.
320
A reduction in the catheter-associated bacterial biofilm load may not be sufficient to cure CRBSI in 321 patients with impaired immune systems (45). In our in vivo study, a single instillation of the gentamicin- Gram-negative pathogens is of some concern, these bacteria are often overlooked in studies using 329 catheter-related infections (8, 20, 42) . In the case of P. aeruginosa CRBSI, treatment failures are 330 frequent and conservative management is often excluded (30). Gentamicin-EDTA could be an 331 excellent candidate lock for such patients, as it extends the possibility of conservative therapy.
332
In summary, we conclude that gentamicin-EDTA effectively eradicated the in vivo TIVAP-associated 333 biofilms of all tested strains. Gentamicin and ethanol were also effective at reducing MSSA biofilm, but
334
were not able to completely eradicate the biofilm from implanted TIVAP. In light of these results, we 335 believe that the gentamicin-EDTA lock deserves further exploration for use in clinical practice. 
551
were contaminated with MSSA and allowed to form biofilm for 3 days prior to ALT instillation and 552
